We hypothesized that this group could include genuine patients with CML (for example, prediagnosis or treated), BCR::ABL1 artefacts, or BCR::ABL1 in non-HSPCs. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.